The DOI matches its Crossref record; 717 of the 717 references it cites were found in a registry or an index.
ImmunoPET: Concept, Design, and Applications
Open accessAbstract
Immuno-positron emission tomography (immunoPET) is a paradigm-shifting molecular imaging modality combining the superior targeting specificity of monoclonal antibody (mAb) and the inherent sensitivity of PET technique. A variety of radionuclides and mAbs have been exploited to develop immunoPET probes, which has been driven by the development and optimization of radiochemistry and conjugation strategies. In addition, tumor-targeting vectors with a short circulation time (e.g., Nanobody) or with an enhanced binding affinity (e.g., bispecific antibody) are being used to design novel immunoPET probes. Accordingly, several immunoPET probes, such as 89 Zr-Df-pertuzumab and 89 Zr-atezolizumab, have been successfully translated for clinical use. By noninvasively and dynamically revealing the expression of heterogeneous tumor antigens, immunoPET imaging is gradually changing the theranostic landscape of several types of malignancies. ImmunoPET is the method of choice for imaging specific tumor markers, immune cells, immune checkpoints, and inflammatory processes. Furthermore, the integration of immunoPET imaging in antibody drug development is of substantial significance because it provides pivotal information regarding antibody targeting abilities and distribution profiles. Herein, we present the latest immunoPET imaging strategies and their preclinical and clinical applications. We also emphasize current conjugation strategies that can be leveraged to develop next-generation immunoPET probes. Lastly, we discuss practical considerations to tune the development and translation of immunoPET imaging strategies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 401–600 of 717
p95HER2–T cell bispecific antibody for breast cancer treatment
Ruiz, I. R., Vicario, R., Morancho, B., Morales, C. B., Arenas, E. J., Herter, S., Freimoser–Grundschober, A., Somandin, J., Sam, J., Ast, O., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aat1445 · Cited by 84
Integrating molecular nuclear imaging in clinical research to improve anticancer therapy
de Vries, E. G. E., de Ruijter, L. K., Hooge, M. N. L., Dierckx, R. A. J. O., Elias, S. G., & Oosting, S. F. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0123-y · Cited by 84
Osada, T., Hsu, D. S., Hammond, S. A., Hobeika, A. C., Devi, G. R., Clay, T. M., Lyerly, H. K., & Morse, M. A. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605364 · Cited by 82
Positron emission tomography imaging of CD105 expression with 89Zr-Df-TRC105
Hong, H., Severin, G. W., Yang, Y., Engle, J. W., Zhang⋆, Y., Barnhart, T. E., Liu, G., Leigh, B. R., Nickles, R. J., & Cai, W. (2011) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-011-1930-x · Cited by 82
Self-citationSkovgaard, D. C., Persson, M., Brandt-Larsen, M., Christensen, C. L., Madsen, J., Klausen, T. L., Holm, S., Andersen, F. L., Loft, A., Berthelsen, A. K., et al. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.116.178970 · Cited by 82
Stefan, N., Gébleux, R., Waldmeier, L., Hell, T., Escher, M., Wolter, F. I., Grawunder, U., & Beerli, R. R. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0688 · Cited by 82
Werner, R. A., Weich, A., Kircher, M., Sólnes, L. B., Javadi, M. S., Higuchi, T., Buck, A. K., Pomper, M. G., Rowe, S. P., & Lapa, C. (2018) · Theranostics · doi:10.7150/thno.30357 · Cited by 82
Hagemann, U. B., Wickstroem, K., Wang, E., Shea, A. O., Sponheim, K., Karlsson, J., Bjerke, R. M., Ryan, O. B., & Cuthbertson, A. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0251 · Cited by 81
Duffy, A. G., Ma, C., Ulahannan, S. V., Rahma, O. E., Makarova‐Rusher, O. V., Cao, L., Yu, Y., Kleiner, D. E., Trepel, J. B., Lee, M.-J., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-3171 · Cited by 81
Wängler, C., Niedermoser, S., Chin, J., Orchowski, K., Schirrmacher, E. S., Jurkschat, K., Iovkova-Berends, L., Kostikov, A. P., Schirrmacher, R., & Wängler, B. (2012) · Nature Protocols · doi:10.1038/nprot.2012.109 · Cited by 80
Efficient [18F]AlF Radiolabeling of ZHER3:8698 Affibody Molecule for Imaging of HER3 Positive Tumors
Pieve, C. D., Allott, L., Martins, C. D., Vardon, A., Ciobota, D. M., Krämer-Marek, G., & Smith, G. S. T. (2016) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.6b00259 · Cited by 80
Copper 64–labeled daratumumab as a PET/CT imaging tracer for multiple myeloma
Caserta, E., Chea, J., Minnix, M., Poku, E. K., Viola, D., Vonderfecht, S. L., Yazaki, P. J., Crow, D. M., Khalife, J., Sanchez, J. F., et al. (2018) · Blood · doi:10.1182/blood-2017-09-807263 · Cited by 80
Miao, Z., Ren, G., Liu, H., Jiang, L., & Cheng, Z. (2010) · Bioconjugate Chemistry · doi:10.1021/bc900515p · Cited by 79
Liersch, T., Meller, J., Bittrich, M., Kulle, B., Becker, H., & Goldenberg, D. M. (2007) · Annals of Surgical Oncology · doi:10.1245/s10434-006-9328-x · Cited by 79
Indium 111-labeled J591 anti-PSMA antibody for vascular targeted imaging in progressive solid tumors
Pandit-Taskar, N. D., O’Donoghue, J. A., Divgi, C. R., Wills, E. A., Schwartz, L. H., Gönen, M., Smith-Jones, P. M., Bander, N. H., Scher, H. I., Larson, S. M., et al. (2015) · EJNMMI Research · doi:10.1186/s13550-015-0104-4 · Cited by 79
Evaluating a Single Domain Antibody Targeting Human PD-L1 as a Nuclear Imaging and Therapeutic Agent
Broos, K., Lecocq, Q., Xavier, C., Bridoux, J., Nguyen, T. T., Corthals, J., Schoonooghe, S., Lion, E., Raes, G., Keyaerts, M., et al. (2019) · Cancers · doi:10.3390/cancers11060872 · Cited by 79
Nayak, T. K., Garmestani, K., Milenic, D. E., & Brechbiel, M. W. (2012) · Journal of Nuclear Medicine · doi:10.2967/jnumed.111.094169 · Cited by 78
Comparison of DOTA and NODAGA as chelators for 64Cu-labeled immunoconjugates
Ghosh, S. C., Pinkston, K. L., Robinson, H., Harvey, B. R., Wilganowski, N. L., Gore, K., Sevick-Muraca, E. M., & Azhdarinia, A. (2014) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2014.09.009 · Cited by 78
Mumprecht, V., Honer, M., Vigl, B., Proulx, S. T., Trachsel, E., Kaspar, M., Bänziger-Tobler, N. E., Schibli, R., Neri, D., & Detmar, M. J. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0896 · Cited by 78
Immuno-targeting the multifunctional CD38 using nanobody
Li, T., Qi, S., Unger, M., Hou, Y. N., Deng, Q. W., Liu, J., Lam, C. M. C., Wang, X. W., Du, X., Zhang, P., et al. (2016) · Scientific Reports · doi:10.1038/srep27055 · Cited by 78
Self-citationPreclinical Development of CD38-Targeted [89Zr]Zr-DFO-Daratumumab for Imaging Multiple Myeloma
Ghai, A., Maji, D., Cho, N., Chanswangphuwana, C., Rettig, M. P., Shen, D., DiPersio, J. F., Akers, W. J., Dehdashti, F., Achilefu, S., et al. (2017) · Journal of Nuclear Medicine · doi:10.2967/jnumed.117.196063 · Cited by 78
van Oordt, C. W. M. D. H., McGeoch, A. T., Bergström, M., McSherry, I. N., Smith, D. A., Cleveland, M., Al‐Azzam, W., Chen, L., Verheul, H. M. W., Hoekstra, O. S., et al. (2019) · Journal of Nuclear Medicine · doi:10.2967/jnumed.118.214726 · Cited by 78
Sharkey, R. M., Rossi, E. A., McBride, W. J., Chang, C., & Goldenberg, D. M. (2010) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2009.12.002 · Cited by 77
Radionuclide‐Activated Nanomaterials and Their Biomedical Applications
Ferreira, C. A., Ni, D., Rosenkrans, Z. T., & Cai, W. (2019) · Angewandte Chemie International Edition · doi:10.1002/anie.201900594 · Cited by 77
Self-citationVento, J. A., Mulgaonkar, A., Woolford, L., Nham, K., Christie, A. L., Bagrodia, A., de Leon, A. D., Hannan, R., Bowman, I. A., McKay, R. M., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0607-z · Cited by 77
Imaging Androgen Receptor Signaling with a Radiotracer Targeting Free Prostate-Specific Antigen
Ulmert, D., Evans, M. J., Holland, J. P., Rice, S. L., Wongvipat, J., Pettersson, K. S. I., Abrahamsson, P.-A., Scardino, P. T., Larson, S. M., Lilja, H. G., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0316 · Cited by 76
A Highly Efficient Copper‐Mediated Radioiodination Approach Using Aryl Boronic Acids
Zhang, P., Zhuang, R., Guo, Z., Su, X., Chen, X. S., & Zhang, X. (2016) · Chemistry - A European Journal · doi:10.1002/chem.201604105 · Cited by 76
Orcutt, K. D., Slusarczyk, A. L., Cieslewicz, M., Ruiz-Yi, B., Bhushan, K. R., Frangioni, J. V., & Wittrup, K. D. (2010) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2010.08.013 · Cited by 75
PET imaging of HER1-expressing xenografts in mice with 86Y-CHX-A″-DTPA-cetuximab
Nayak, T. K., Regino, C. A. S., Wong, K. J., Milenic, D. E., Garmestani, K., Baidoo, K. E., Szajek, L. P., & Brechbiel, M. W. (2010) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-009-1370-z · Cited by 75
Elsässer‐Beile, U., Wolf, P., Gierschner, D., Bühler, P., Schultze‐Seemann, W., & Wetterauer, U. (2006) · The Prostate · doi:10.1002/pros.20367 · Cited by 75
A phase II study of radioimmunotherapy with intraventricular 131I‐3F8 for medulloblastoma
Kramer, K., Pandit-Taskar, N. D., Humm, J. L., ZANZONICO, P. B., Haque, S. S., Dunkel, I. J., Wolden, S. L., Donzelli, M. A., Goldman, D. A., Lewis, J. S., et al. (2017) · Pediatric Blood & Cancer · doi:10.1002/pbc.26754 · Cited by 75
Efficient and irreversible antibody–cysteine bioconjugation using carbonylacrylic reagents
Bernardim, B., Matos, M. J., Ferhati, X., Compañón, I., Guerreiro, A., Akkapeddi, P., Burtoloso, A. C. B., Jiménez‐Osés, G., Corzana, F., & Bernardes, G. J. L. (2018) · Nature Protocols · doi:10.1038/s41596-018-0083-9 · Cited by 75
Sato, N., Stringaris, K., Davidson-Moncada, J. K., Reger, R. N., Adler, S., Dunbar, C. E., Choyke, P. L., & Childs, R. W. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2897 · Cited by 75
Viola, N. T., Sevak, K. K., Carlin, S., Doran, M. G., Evans, H. W., Bartlett, D. W., Wu, A. M., & Lewis, J. S. (2014) · Molecular Pharmaceutics · doi:10.1021/mp500164r · Cited by 74
Vugts, D. J., Vervoort, A., van Walsum, M., Visser, G. W. M., Robillard, M. S., Versteegen, R. M., Vulders, R. C. M., Herscheid, J. D. M., & van Dongen, G. A. M. S. (2011) · Bioconjugate Chemistry · doi:10.1021/bc200298v · Cited by 74
Recombinant Anti-CD20 Antibody Fragments for Small-Animal PET Imaging of B-Cell Lymphomas
Olafsen, T., Betting, D. J., Kenanova, V. E., Salazar, F. B., Clarke, P. J., SAID, J. W., Raubitschek, A. A., Timmerman, J. M., & Wu, A. M. (2009) · Journal of Nuclear Medicine · doi:10.2967/jnumed.108.060426 · Cited by 74
Application of Monoclonal Antibody G250 Recognizing Carbonic Anhydrase IX in Renal Cell Carcinoma
Oosterwijk‐Wakka, J. C., Boerman, O. C., Mulders, P., & Oosterwijk, E. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms140611402 · Cited by 73
Hong, H., Zhang, Y., Severin, G. W., Yang, Y., Engle, J. W., Niu, G., Nickles, R. J., Chen, X. S., Leigh, B. R., Barnhart, T. E., et al. (2012) · Molecular Pharmaceutics · doi:10.1021/mp300277f · Cited by 72
Self-citationRadioimmunoconjugates for the Treatment of Cancer
Kraeber‐Bodéré, F., Bodet‐Milin, C., Rousseau, C., Eugène, T., Pallardy, A., Frampas, É., Carlier, T., Ferrer, L., Gaschet, J., Davodeau, F., et al. (2014) · Seminars in Oncology · doi:10.1053/j.seminoncol.2014.07.004 · Cited by 72
Bodet‐Milin, C., Faivre-Chauvet, A., Carlier, T., Rauscher, A., Bourgeois, M., Cerato, E., Rohmer, V., Couturier, O., Drui, D., Goldenberg, D. M., et al. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.116.172221 · Cited by 72
Bensch, F., Lamberts, L. E., Smeenk, M. M., Jorritsma‐Smit, A., Hooge, M. N. L., van Scheltinga, A. G. T. T., de Jong, J. R., Gietema, J. A., Schröder, C. P., Thomas, M., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0311 · Cited by 72
Immuno-PET in Inflammatory Bowel Disease: Imaging CD4-Positive T Cells in a Murine Model of Colitis
Freise, A. C., Zettlitz, K. A., Salazar, F. B., Tavaré, R., Tsai, W. K., Chatziioannou, A. F., Rozengurt, N., Braun, J. G., & Wu, A. M. (2018) · Journal of Nuclear Medicine · doi:10.2967/jnumed.117.199075 · Cited by 72
Photoimmunoconjugates: novel synthetic strategies to target and treat cancer by photodynamic therapy
Fernandes, S., Fernandes, R., Sarmento, B. F. C. C., Pereira, P. M. R., & Tomé, J. P. C. (2019) · Organic & Biomolecular Chemistry · doi:10.1039/c8ob02902d · Cited by 72
The Impact of FcγRI Binding on Immuno-PET
Vivier, D., Sharma, S. K., Adumeau, P., Rodríguez, C. M. A., Fung, K., & Zeglis, B. M. (2019) · Journal of Nuclear Medicine · doi:10.2967/jnumed.118.223636 · Cited by 72
Pre-clinical Imaging of Invasive Candidiasis Using ImmunoPET/MR
Morad, H. O. J., Wild, A., Wiehr, S., Davies, G. E., Maurer, A., Pichler, B. J., & Thornton, C. R. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.01996 · Cited by 71
Gordon, M. S., Robert, F., Matei, D. E., Mendelson, D. S., Goldman, J. W., Chiorean, E. G., Strother, R. M., Seon, B. K., Figg, W. D., Peer, C. J., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1143 · Cited by 70
Long-term CD38 saturation by daratumumab interferes with diagnostic myeloma cell detection
Oberle, A., Brandt, A. P., Alawi, M., Langebrake, C., Janjetovic, S., Wolschke, C., Schütze, K., Bannas, P., Kröger, N. M., Koch‐Nolte, F., et al. (2017) · Haematologica · doi:10.3324/haematol.2017.169235 · Cited by 70
Theranostic Radiolabeled Anti-CD20 sdAb for Targeted Radionuclide Therapy of Non-Hodgkin Lymphoma
Krasniqi, A., D’Huyvetter, M., Xavier, C., der Jeught, K. V., Muyldermans, S., der Heyden, J. V., Lahoutte, T., Tavernier, J. H., & Devoogdt, N. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0554 · Cited by 70
Lesniak, W. G., Chu, C., Jabłońska, A., Du, Y., Pomper, M. G., Walczak, P., & Janowski, M. (2018) · Journal of Nuclear Medicine · doi:10.2967/jnumed.118.218792 · Cited by 70
Lohrmann, C., O'Reilly, E. M., O’Donoghue, J. A., Pandit-Taskar, N. D., Carrasquillo, J. A., Lyashchenko, S. K., Ruan, S., Teng, R. S. Y., Scholz, W. W., Maffuid, P. W., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3667 · Cited by 70
Fumey, W., Koenigsdorf, J., Kunick, V., Menzel, S., Schütze, K., Unger, M., Schriewer, L., Haag, F., Adam, G., Oberle, A., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-14112-6 · Cited by 69
Feasibility of Affibody Molecule-Based PNA-Mediated Radionuclide Pretargeting of Malignant Tumors
Honarvar, H., Westerlund, K., Altai, M., Sandström, M., Orlova, A., Максимилианович, Т. В., & Karlström, A. E. (2015) · Theranostics · doi:10.7150/thno.12766 · Cited by 68
Bensch, F., Smeenk, M. M., van Es, S. C., de Jong, J. R., Schroder, C. P., Oosting, S. F., Hooge, M. N. L., van Oordt, C. W. M. D. H., Brouwers, A. H., Boellaard, R., et al. (2018) · Theranostics · doi:10.7150/thno.26370 · Cited by 68
Rowe, S. P., Gorin, M. A., & Pomper, M. G. (2019) · Annual Review of Medicine · doi:10.1146/annurev-med-062117-073027 · Cited by 68
Affibody-mediated PET imaging of HER3 expression in malignant tumours
Rosestedt, M., Andersson, K. G., Mitran, B., Максимилианович, Т. В., Löfblom, J., Orlova, A., & Ståhl, S. (2015) · Scientific Reports · doi:10.1038/srep15226 · Cited by 67
Viola, N. T., Rice, S. L., Carlin, S., Wu, X., Evans, M. J., Sevak, K. K., Drobjnak, M., Ragupathi, G., Sawada, R., Scholz, W. W., et al. (2013) · Journal of Nuclear Medicine · doi:10.2967/jnumed.113.119867 · Cited by 67
Whither Radioimmunotherapy: To Be or Not To Be?
Green, D. J., & Press, O. W. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2523 · Cited by 67
Spycher, P. R., Amann, C. A., Wehrmüller, J. E., Hurwitz, D. R., Kreis, O., Messmer, D., Ritler, A., Küchler, A., Blanc, A., Béhé, M. P., et al. (2017) · ChemBioChem · doi:10.1002/cbic.201700188 · Cited by 67
Rossi, S., Toschi, L., Castello, A., Grizzi, F., Mansi, L., & Lopci, E. (2017) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-017-3802-5 · Cited by 67
Vugmeyster, Y., Entrican, C., Joyce, A. P., Lawrence-Henderson, R. F., Leary, B. A., Mahoney, C. S., Patel, H. K., Raso, S. W., Olland, S., Hegen, M., et al. (2012) · Bioconjugate Chemistry · doi:10.1021/bc300066a · Cited by 66
Nanobodies detecting and modulating GPCRs outside in and inside out
Heukers, R., Groof, T. W. M. D., & Smit, M. J. (2019) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2019.01.003 · Cited by 66
Jauw, Y. W. S., O’Donoghue, J. A., Zijlstra, J. M., Hoekstra, O. S., van Oordt, C. W. M. D. H., Morschhauser, F., Carrasquillo, J. A., Zweegman, S., Pandit-Taskar, N. D., Lammertsma, A. A., et al. (2019) · Journal of Nuclear Medicine · doi:10.2967/jnumed.118.224568 · Cited by 66
Bu, P., Gao, L., Zhuang, J., Feng, J., Yang, D., & Yan, X. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0260 · Cited by 65
Rossin, R., Berndorff, D., Friebe, M., Dinkelborg, L. M., & Welch, M. J. (2007) · Journal of Nuclear Medicine · doi:10.2967/jnumed.107.040477 · Cited by 65
Rashidian, M., Wang, L., Edens, J. G., Jacobsen, J. T., Hossain, I., Wang, Q., Victora, G. D., Vasdev, N., Ploegh, H. L., & Liang, S. H. (2015) · Angewandte Chemie International Edition · doi:10.1002/anie.201507596 · Cited by 65
Green, D. J., O’Steen, S., Lin, Y., Comstock, M., Kenoyer, A. L., Hamlin, D. K., Wilbur, D. S., Fisher, D. R., Nartea, M. E., Hylarides, M. D., et al. (2017) · Blood · doi:10.1182/blood-2017-09-807610 · Cited by 65
Carrasquillo, J. A., Fine, B. M., Pandit-Taskar, N. D., Larson, S. M., Fleming, S. E., Fox, J. J., Cheal, S. M., O’Donoghue, J. A., Ruan, S., Ragupathi, G., et al. (2019) · Journal of Nuclear Medicine · doi:10.2967/jnumed.118.222844 · Cited by 65
Westerlund, K., Altai, M., Mitran, B., Konijnenberg, M., Oroujeni, M., Atterby, C., de Jong, M., Orlova, A., Mattsson, J. S. M., Micke, P., et al. (2018) · Journal of Nuclear Medicine · doi:10.2967/jnumed.118.208348 · Cited by 64
Davies, G., Rolle, A.-M., Maurer, A., Spycher, P. R., Schillinger, C., Solouk-Saran, D., Hasenberg, M., Weski, J., Fonslet, J., Dubois, A., et al. (2017) · Theranostics · doi:10.7150/thno.20919 · Cited by 63
Evaluation of strained alkynes for Cu-free click reaction in live mice
van den Bosch, S. M., Rossin, R., Verkerk, P. R., ten Hoeve, W., Janssen, H. M., Lub, J., & Robillard, M. S. (2013) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2012.12.006 · Cited by 63
Everolimus Reduces 89Zr-Bevacizumab Tumor Uptake in Patients with Neuroendocrine Tumors
van Asselt, S. J., Oosting, S. F., Brouwers, A. H., Bongaerts, A. H. H., de Jong, J. R., Hooge, M. N. L., Munnink, T. H. O., Fiebrich, H., Sluiter, W. J., Links, T. P., et al. (2014) · Journal of Nuclear Medicine · doi:10.2967/jnumed.113.129056 · Cited by 63
PET of EGFR Expression with an 18F-Labeled Affibody Molecule
Miao, Z., Ren, G., Liu, H., Qi, S., Wu, S., & Cheng, Z. (2012) · Journal of Nuclear Medicine · doi:10.2967/jnumed.111.100842 · Cited by 63
Advances in Imaging Specific Mediators of Inflammatory Bowel Disease
Dmochowska, N., Wardill, H. R., & Hughes, P. A. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19092471 · Cited by 63
Максимилианович, Т. В., Varasteh, Z., Honarvar, H., Hosseinimehr, S. J., Eriksson, O., Jonasson, P., Frejd, F. Y., Abrahmsén, L., & Orlova, A. (2014) · Journal of Nuclear Medicine · doi:10.2967/jnumed.113.121814 · Cited by 62
Immuno-PET of the Hepatocyte Growth Factor Receptor Met Using the 1-Armed Antibody Onartuzumab
Jagoda, E. M., Lang, L., Veerendra, B., Histed, S. N., Williams, M. R., Krämer-Marek, G., Mena, E., Rosenblum, L. T., Mařı́k, J., Tinianow, J. N., et al. (2012) · Journal of Nuclear Medicine · doi:10.2967/jnumed.111.102293 · Cited by 62
Feasibility of Affibody-Based Bioorthogonal Chemistry–Mediated Radionuclide Pretargeting
Altai, M., Perols, A., Tsourma, M., Mitran, B., Honarvar, H., Robillard, M. S., Rossin, R., ten Hoeve, W., Lubberink, M., Orlova, A., et al. (2015) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.162248 · Cited by 62
Molecular imaging of T cell co-regulator factor B7-H3 with 89Zr-DS-5573a
Burvenich, I. J. G., Parakh, S., Lee, F.-T., Guo, N. Y., Liu, Z., Gan, H. K., Rigopoulos, A., O'Keefe, G. J., Gong, S. J., Goh, Y. W., et al. (2018) · Theranostics · doi:10.7150/thno.25575 · Cited by 62
Karzai, F. H., Apolo, A. B., Cao, L., Madan, R. A., Adelberg, D. E., Parnes, H. L., McLeod, D. G., Harold, N., Peer, C. J., Yu, Y., et al. (2014) · British Journal of Urology · doi:10.1111/bju.12986 · Cited by 61
Gallium-68-Labeled Affibody Molecule for PET Imaging of PDGFRβ Expression in Vivo
Strand, J., Varasteh, Z., Eriksson, O., Abrahmsén, L., Orlova, A., & Максимилианович, Т. В. (2014) · Molecular Pharmaceutics · doi:10.1021/mp500284t · Cited by 61
Immuno-PET Imaging of Engineered Human T Cells in Tumors
Mall, S., Yusufi, N., Wagner, R., Klar, R., Bianchi, H. D. O., Steiger, K., Straub, M., Audehm, S., Laitinen, I., Aichler, M., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2784 · Cited by 61
Nigam, S., McCarl, L. H., Kumar, R., Edinger, R. S., Kurland, B. F., Anderson, C. J., Panigrahy, A., Kohanbash, G., & Edwards, W. B. (2019) · Molecular Imaging and Biology · doi:10.1007/s11307-019-01427-1 · Cited by 61
PET with the89Zr-Labeled Transforming Growth Factor-β Antibody Fresolimumab in Tumor Models
Munnink, T. H. O., Arjaans, M., Timmer‐Bosscha, H., Schroder, C. P., Hesselink, J. W., Vedelaar, S. R., Walenkamp, A., Reiß, M., Gregory, R. C., Hooge, M. N. L., et al. (2011) · Journal of Nuclear Medicine · doi:10.2967/jnumed.111.092809 · Cited by 60
Jeong, H., Abhiraman, G. C., Story, C. M., Ingram, J. R., & Dougan, S. K. (2017) · PLoS ONE · doi:10.1371/journal.pone.0189068 · Cited by 60
O’Steen, S., Comstock, M., Orozco, J. J., Hamlin, D. K., Wilbur, D. S., Jones, J. C., Kenoyer, A. L., Nartea, M. E., Lin, Y., Miller, B. W., et al. (2019) · Blood · doi:10.1182/blood.2019001250 · Cited by 60
A pretargeting system for tumor PET imaging and radioimmunotherapy
Kraeber‐Bodéré, F., Rousseau, C., Bodet‐Milin, C., Frampas, É., Faivre-Chauvet, A., Rauscher, A., Sharkey, R. M., Goldenberg, D. M., Chatal, J., & Barbet, J. (2015) · Frontiers in Pharmacology · doi:10.3389/fphar.2015.00054 · Cited by 59
Chang, A. J., Silva, R. A. D., & Lapi, S. E. (2013) · PubMed · doi:10.2310/7290.2012.00016 · Cited by 59
Garousi, J., ANDERSSON, K. G., Mitran, B., PICHL, M.-L., Ståhl, S., Orlova, A., Löfblom, J., & Максимилианович, Т. В. (2016) · International Journal of Oncology · doi:10.3892/ijo.2016.3369 · Cited by 59
Comparison of Two Site-Specifically 18F-Labeled Affibodies for PET Imaging of EGFR Positive Tumors
Su, X., Cheng, K., Jeon, J., Shen, B., Venturin, G. T., Hu, X., Rao, J., Chin, F. T., Wu, H., & Cheng, Z. (2014) · Molecular Pharmaceutics · doi:10.1021/mp5003043 · Cited by 59
van Elssen, C. H. M. J., Rashidian, M., Vrbanac, V. D., Wucherpfennig, K. W., Habre, Z. E., Sticht, J., Freund, C., Jacobsen, J. T., Cragnolini, J., Ingram, J. R., et al. (2017) · Journal of Nuclear Medicine · doi:10.2967/jnumed.116.186007 · Cited by 59
CD146‐Targeted Multimodal Image‐Guided Photoimmunotherapy of Melanoma
Wei, W., Jiang, D., Ehlerding, E. B., Barnhart, T. E., Yang, Y., Engle, J. W., Luo, Q., Huang, P., & Cai, W. (2019) · Advanced Science · doi:10.1002/advs.201801237 · Cited by 59
Self-citationKnowles, S. M., Zettlitz, K. A., Tavaré, R., Rochefort, M. M., Salazar, F. B., Stout, D. B., Yazaki, P. J., Reiter, R. E., & Wu, A. M. (2014) · Journal of Nuclear Medicine · doi:10.2967/jnumed.113.120873 · Cited by 58
Pretargeting for imaging and therapy in oncological nuclear medicine
Bailly, C., Bodet‐Milin, C., Rousseau, C., Faivre-Chauvet, A., Kraeber‐Bodéré, F., & Barbet, J. (2017) · EJNMMI Radiopharmacy and Chemistry · doi:10.1186/s41181-017-0026-8 · Cited by 58
Senders, M. L., Que, X., Cho, Y. S., Yeang, C., Groenen, H., Fay, F., Calcagno, C., Meerwaldt, A. E., Green, S., Miu, P., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.11.036 · Cited by 58
Moek, K. L., Waaijer, S. J. H., Kok, I. C., Suurs, F. V., Brouwers, A. H., van Oordt, C. W. M. D. H., Wind, T. T., Gietema, J. A., Schröder, C. P., Mahesh, S. V. K., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2918 · Cited by 58
van Rij, C. M., Lütje, S., Frielink, C., Sharkey, R. M., Goldenberg, D. M., Franssen, G. M., McBride, W. J., Rossi, E. A., Oyen, W. J. G., & Boerman, O. C. (2013) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-013-2434-7 · Cited by 57
Bahce, I., Huisman, M. C., Verwer, E. E., Ooijevaar, R. E., Boutkourt, F., Vugts, D. J., van Dongen, G. A. M. S., Boellaard, R., & Smit, E. F. (2014) · EJNMMI Research · doi:10.1186/s13550-014-0035-5 · Cited by 57
Sandberg, D., Максимилианович, Т. В., Velikyan, I., Olofsson, H., Wennborg, A., Feldwisch, J., Carlsson, J., Lindman, H., & Sørensen, J. (2017) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-017-3650-3 · Cited by 57
Wickstroem, K., Hagemann, U. B., Cruciani, V., Wengner, A. M., Kristian, A., Ellingsen, C., Siemeister, G., Bjerke, R. M., Karlsson, J., Ryan, O. B., et al. (2019) · Journal of Nuclear Medicine · doi:10.2967/jnumed.118.223701 · Cited by 57
Sharkey, R. M., Karacay, H., Vallabhajosula, S., McBride, W. J., Rossi, E. A., Chang, C., Goldsmith, S. J., & Goldenberg, D. M. (2008) · Radiology · doi:10.1148/radiol.2462070229 · Cited by 56
The art of antibody process development
Steinmeyer, D. E., & McCormick, E. L. (2008) · Drug Discovery Today · doi:10.1016/j.drudis.2008.04.005 · Cited by 56
Orlova, A., Malm, M., Rosestedt, M., Varasteh, Z., Andersson, K. G., Selvaraju, R., Altai, M., Honarvar, H., Strand, J., Ståhl, S., et al. (2014) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-014-2733-7 · Cited by 56
Development of novel radionuclides for medical applications
Qaim, S. M., & Spahn, I. (2017) · Journal of Labelled Compounds and Radiopharmaceuticals · doi:10.1002/jlcr.3578 · Cited by 56
Kumar, K., & Ghosh, A. K. (2018) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.7b00817 · Cited by 56
Characterization of ABBV-221, a Tumor-Selective EGFR-Targeting Antibody Drug Conjugate
Phillips, A. C., Boghaert, E. R., Vaidya, K. S., Falls, H. D., Mitten, M. J., DeVries, P. J., Benatuil, L., Hsieh, C.-M., Meulbroek, J. A., Panchal, S. C., et al. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0710 · Cited by 56
van Scheltinga, A. G. T. T., Hooge, M. N. L., Abiraj, K., Schröder, C. P., Pot, L., Bossenmaier, B., Thomas, M., Hölzlwimmer, G., Friess, T., Kosterink, J. G. W., et al. (2014) · mAbs · doi:10.4161/mabs.29097 · Cited by 55
HaloTag, a Platform Technology for Protein Analysis
Urh, M. (2012) · Current Chemical Genomics · doi:10.2174/1875397301206010072 · Cited by 55
Alt, K., Paterson, B. M., Westein, E., Rudd, S. E., Poniger, S. S., Jagdale, S., Ardipradja, K., Connell, T. U., Krippner, G. Y., Nair, A. K. N., et al. (2015) · Angewandte Chemie International Edition · doi:10.1002/anie.201411507 · Cited by 55
A Preclinical Model of CD38-Pretargeted Radioimmunotherapy for Plasma Cell Malignancies
Green, D. J., Orgun, N. N., Jones, J. C., Hylarides, M. D., Pagel, J. M., Hamlin, D. K., Wilbur, D. S., Lin, Y., Fisher, D. R., Kenoyer, A. L., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-1589 · Cited by 55
Heskamp, S., Hernandez, R. T., Molkenboer‐Kuenen, J. D. M., Essler, M., Bruchertseifer, F., Morgenstern, A., Steenbergen, E. J., Cai, W., Seidl, C., McBride, W. J., et al. (2017) · Journal of Nuclear Medicine · doi:10.2967/jnumed.116.187021 · Cited by 55
Self-citationDual-Targeted Molecular Imaging of Cancer
Ehlerding, E. B., Sun, L., Lan, X., Zeng, D., & Cai, W. (2018) · Journal of Nuclear Medicine · doi:10.2967/jnumed.117.199877 · Cited by 55
Self-citationNayak, T. K., Garmestani, K., Milenic, D. E., Baidoo, K. E., & Brechbiel, M. W. (2011) · PLoS ONE · doi:10.1371/journal.pone.0018198 · Cited by 54
Site-Specific Immuno-PET Tracer to Image PD-L1
Wissler, H. L., Ehlerding, E. B., Lyu, Z., Zhao, Y., Zhang, S., Eshraghi, A. R., Buuh, Z. Y., McGuth, J. C., Guan, Y., Engle, J. W., et al. (2019) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.9b00010 · Cited by 54
Self-citationYoon, S. O., Lee, T. S., Kim, S. J., Jang, M. H., Kang, Y. J., Park, J. H., Kim, K., Lee, H. S., Ryu, C. J., Gonzales, N. R., et al. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m511165200 · Cited by 53
Ahmadzadehfar, H., Rahbar, K., Essler, M., & Biersack, H. J. (2019) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2019.07.003 · Cited by 53
Development of new multivalent-bispecific agents for pretargeting tumor localization and therapy.
Rossi, E. A., Sharkey, R. M., McBride, W., Karacay, H., Li, Z., Hansen, H. J., Goldenberg, D. M., & Chang, C. (2003) · PubMed · Cited by 52
Zeng, D., Guo, Y., White, A. G., Cai, Z., Modi, J., Ferdani, R., & Anderson, C. J. (2014) · Molecular Pharmaceutics · doi:10.1021/mp500004m · Cited by 52
Mapping biological behaviors by application of longer-lived positron emitting radionuclides
Zhou, Y., Baidoo, K. E., & Brechbiel, M. W. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.10.012 · Cited by 52
Clinical development of HER3-targeting monoclonal antibodies: Perils and progress
Jacob, W., James, I., Hasmann, M., & Weisser, M. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.06.011 · Cited by 52
Interest of Pet Imaging in Multiple Myeloma
Jamet, B., Bailly, C., Carlier, T., Touzeau, C., Nanni, C., Zamagni, E., Barré, L., Michaud, A.-V., Chérel, M., Moreau, P., et al. (2019) · Frontiers in Medicine · doi:10.3389/fmed.2019.00069 · Cited by 52
Platelet‐derived growth factor receptor‐α promotes lymphatic metastases in papillary thyroid cancer
Zhang, J., Wang, P., Dykstra, M. A., Gélébart, P., Williams, D., Ingham, R. J., Adewuyi, E. E., Lai, R. L., & McMullen, T. P. W. (2012) · The Journal of Pathology · doi:10.1002/path.4069 · Cited by 51
Zettlitz, K. A., Tavaré, R., Knowles, S. M., Steward, K. K., Timmerman, J. M., & Wu, A. M. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0855 · Cited by 51
Molecular imaging of β-cells: diabetes and beyond
Wei, W., Ehlerding, E. B., Lan, X., Luo, Q., & Cai, W. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.06.022 · Cited by 51
Self-citationKaracay, H., Sharkey, R. M., McBride, W. J., Griffiths, G. L., Qu, Z., Chang, K.-M., Hansen, H. J., & Goldenberg, D. M. (2002) · Bioconjugate Chemistry · doi:10.1021/bc0200172 · Cited by 50
Schoffelen, R., van der Graaf, W. T. A., Franssen, G. M., Sharkey, R. M., Goldenberg, D. M., McBride, W. J., Rossi, E. A., Eek, A., Oyen, W. J. G., & Boerman, O. C. (2010) · Journal of Nuclear Medicine · doi:10.2967/jnumed.110.079376 · Cited by 50
Breast cancer imaging with radiolabeled antibodies
Goldenberg, D. M., & Nabi, H. A. (1999) · Seminars in Nuclear Medicine · doi:10.1016/s0001-2998(99)80028-2 · Cited by 50
The Rise of Metal Radionuclides in Medical Imaging: Copper-64, Zirconium-89 and Yttrium-86
Ikotun, O. F., & Lapi, S. E. (2011) · Future Medicinal Chemistry · doi:10.4155/fmc.11.14 · Cited by 50
Teiluf, K., Seidl, C., Blechert, B., Gaertner, F. C., Gilbertz, K.-P., Fernández‐Sáiz, V., Bassermann, F. C., Endell, J., Boxhammer, R., Leclair, S., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2986 · Cited by 50
Rossi, E. A., Chang, C., Losman, M. J., Sharkey, R. M., Karacay, H., McBride, W., Cardillo, T. M., Hansen, H. J., Qu, Z., Horak, I. D., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-1004-0020 · Cited by 50
Cheal, S. M., Xu, H., Guo, H.-F., Lee, S., Punzalan, B. J., Chalasani, S., Fung, E. K., Jungbluth, A. A., ZANZONICO, P. B., Carrasquillo, J. A., et al. (2015) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-015-3254-8 · Cited by 50
Bruijnen, S. T. G., Tsang-A-Sjoe, M. W. P., Raterman, H. G., Ramwadhdoebé, T. H., Vugts, D. J., van Dongen, G. A. M. S., Huisman, M. C., Hoekstra, O. S., Tak, P. P., Voskuyl, A. E., et al. (2016) · Arthritis Research & Therapy · doi:10.1186/s13075-016-1166-z · Cited by 50
Santangelo, P. J., Cicala, C., Byrareddy, S. N., Ortiz, K., Little, D. M., Lindsay, K. E., Gumber, S., Hong, J. J., Jelicic, K., Rogers, K. A., et al. (2017) · Mucosal Immunology · doi:10.1038/mi.2017.112 · Cited by 50
ImmunoPET imaging of CD38 in murine lymphoma models using 89Zr-labeled daratumumab
Kang, L., Jiang, D., England, C. G., Barnhart, T. E., Yu, B., Rosenkrans, Z. T., Wang, R., Engle, J. W., Xu, X., Huang, P., et al. (2018) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-018-3941-3 · Cited by 50
Self-citationLawrentschuk, N., Lee, F.-T., Jones, G. R., Rigopoulos, A., Mountain, A. J., O'Keefe, G. J., Papenfuss, A. T., Bolton, D. M., Davis, I. D., & Scott, A. M. (2009) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2009.03.028 · Cited by 49
Karacay, H., Sharkey, R. M., Gold, D. V., Ragland, D. R., McBride, W. J., Rossi, E. A., Chang, C., & Goldenberg, D. M. (2009) · Journal of Nuclear Medicine · doi:10.2967/jnumed.109.067686 · Cited by 49
Orcutt, K. D., Rhoden, J. J., Ruiz-Yi, B., Frangioni, J. V., & Wittrup, K. D. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0764 · Cited by 49
Campbell, D. O., Noda, A., Verlinsky, A., Snyder, J., Fujita, Y., Murakami, Y., Fushiki, H., Miyoshi, S., Lacayo, S., Cabral, E., et al. (2016) · Molecular Imaging and Biology · doi:10.1007/s11307-016-0953-x · Cited by 49
Lam, K., Chan, C., & Reilly, R. M. (2016) · mAbs · doi:10.1080/19420862.2016.1255389 · Cited by 49
A nanobody-based tracer targeting DPP6 for non-invasive imaging of human pancreatic endocrine cells
Balhuizen, A., Massa, S., Mathijs, I., Turatsinze, J., Vos, J. D., Demine, S., Xavier, C., Villate, O., Millard, I., Egrise, D., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-15417-2 · Cited by 49
A review of approaches to 18F radiolabelling affinity peptides and proteins
Morris, O., Fairclough, M., Grigg, J., Prenant, C., & McMahon, A. W. (2018) · Journal of Labelled Compounds and Radiopharmaceuticals · doi:10.1002/jlcr.3634 · Cited by 49
Cheal, S. M., Fung, E. K., Patel, M., Xu, H., Guo, H.-F., ZANZONICO, P. B., Monette, S., Wittrup, K. D., Cheung, N. V., & Larson, S. M. (2017) · Journal of Nuclear Medicine · doi:10.2967/jnumed.117.193250 · Cited by 48
Have Clinical Trials Properly Assessed c-Met Inhibitors?
Hughes, V. S., & Siemann, D. W. (2017) · Trends in cancer · doi:10.1016/j.trecan.2017.11.009 · Cited by 48
Berg, E., Zhang, X., Bec, J., Judenhofer, M. S., Patel, B., Peng, Q., Kapusta, M., Schmand, M. J., Casey, M., Tarantal, A. F., et al. (2018) · Journal of Nuclear Medicine · doi:10.2967/jnumed.117.200519 · Cited by 48
Antibody and fragment-based PET imaging of CTLA-4+ T-cells in humanized mouse models.
Ehlerding, E. B., Lee, H. J., Jiang, D., Ferreira, C. A., Zahm, C. D., Huang, P., Engle, J. W., McNeel, D. G., & Cai, W. (2019) · Europe PMC (PubMed Central) · Cited by 48
Self-citationLindenberg, L., Thomas, A., Adler, S., Mena, E., Kurdziel, K., Maltzman, J. D., Wallin, B., Hoffman, K., Pastan, I. H., Paik, C. H., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.2883 · Cited by 47
Antibody inhibiting enzymatic activity of tumour-associated carbonic anhydrase isoform IX
Murri-Plesko, M. T., Hulíková, A., Oosterwijk, E., Scott, A. M., Zortea, A., Harris, A. L., Ritter, G., Old, L. J., Bauer, S., Swietach, P., et al. (2011) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2011.01.063 · Cited by 47
Desar, I. M. E., Stillebroer, A. B., Oosterwijk, E., Leenders, W. P. J., van Herpen, C. M. L., van der Graaf, W. T. A., Boerman, O. C., Mulders, P., & Oyen, W. J. G. (2010) · Journal of Nuclear Medicine · doi:10.2967/jnumed.110.078030 · Cited by 47
van Scheltinga, A. G. T. T., Ogasawara, A. K., Pacheco, G., Vanderbilt, A. N., Tinianow, J. N., Gupta, N., Li, D., Firestein, R., Mařík, J., Scales, S. J., et al. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0449 · Cited by 47
Warnders, F. J., van Scheltinga, A. G. T. T., Knuehl, C., Roy, M. V., de Vries, E. F. J., Kosterink, J. G. W., de Vries, E. G. E., & Hooge, M. N. L. (2017) · Journal of Nuclear Medicine · doi:10.2967/jnumed.116.181586 · Cited by 47
Dorff, T. B., Longmate, J., Pal, S. K., Stadler, W. M., Fishman, M., Vaishampayan, U. N., Rao, A. R., Pinksi, J. K., Hu, J. S., Quinn, D. I., et al. (2017) · Cancer · doi:10.1002/cncr.30942 · Cited by 47
Molecular Imaging of Invasive Pulmonary Aspergillosis Using ImmunoPET/MRI: The Future Looks Bright
Thornton, C. R. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.00691 · Cited by 47
Xu, M., Han, Y., Liu, G., Xu, Y. Y., Duan, D., Liu, H., Du, F. F., Luo, P. M., & Liu, Z. (2018) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.8b00371 · Cited by 47
Moroz, A., Lee, C.-Y., Wang, Y.-H., Hsiao, J. C., Sevillano, N., Truillet, C., Craik, C. S., Fong, L. H., Wang, C., & Evans, M. J. (2018) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.8b00632 · Cited by 47
Camera, L., Kinuya, S., Garmestani, K., Brechbiel, M. W., Wu, C., Pai, L. H., McMurry, T. J., Gansow, O. A., Pastan, I., Paik, C. H., et al. (1994) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/bf00285586 · Cited by 46
Guo, Y., Ferdani, R., & Anderson, C. J. (2012) · Bioconjugate Chemistry · doi:10.1021/bc300092n · Cited by 46
Comparison of bifunctional chelates for 64Cu antibody imaging
Ferreira, C. L., Yapp, D. T. T., Crisp, S., Sutherland, B. W., Ng, S. S. W., Gleave, M. E., Bensimon, C., Jurek, P. E., & Kiefer, G. E. (2010) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-010-1506-1 · Cited by 46
Panousis, C., Rayzman, V., Johns, T. G., Renner, C., Liu, Z., Cartwright, G. A., Lee, F.-T., Wang, D., Gan, H. K., Cao, D., et al. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602470 · Cited by 46
Parry, R., Schneider, D., Hudson, D. L., Parkes, D., Xuan, J.-A., Newton, A., Toy, P., Lin, R. Y., Harkins, R., Alicke, B., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1203 · Cited by 46
Sonn, G. A., Behesnilian, A. S., Jiang, Z. K., Zettlitz, K. A., Lepin, E. J., Bentolila, L. A., Knowles, S. M., Lawrence, D. J. P., Wu, A. M., & Reiter, R. E. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0503 · Cited by 46
Luo, H., England, C. G., Goel, S., Graves, S. A., Ai, F., Liu, B., Theuer, C. P., Wong, H. C., Nickles, R. J., & Cai, W. (2017) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.6b01123 · Cited by 46
Self-citation68Ga-Labeled PSMA Uptake in Nonprostatic Malignancies
Malik, D., Kumar, R., Mittal, B. R., Singh, H., Bhattacharya, A., & Singh, S. K. (2018) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000002103 · Cited by 46
PET Imaging of Receptor Tyrosine Kinases in Cancer
Wei, W., Ni, D., Ehlerding, E. B., Luo, Q., & Cai, W. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-0087 · Cited by 46
Self-citationPryma, D. A., O’Donoghue, J. A., Humm, J. L., Jungbluth, A. A., Old, L. J., Larson, S. M., & Divgi, C. R. (2011) · Journal of Nuclear Medicine · doi:10.2967/jnumed.110.083295 · Cited by 45
A New Tri-Fab Bispecific Antibody for Pretargeting Trop-2–Expressing Epithelial Cancers
Sharkey, R. M., van Rij, C. M., Karacay, H., Rossi, E. A., Frielink, C., Regino, C. A. S., Cardillo, T. M., McBride, W. J., Chang, C., Boerman, O. C., et al. (2012) · Journal of Nuclear Medicine · doi:10.2967/jnumed.112.104364 · Cited by 45
Enhanced Tumor Retention of a Radiohalogen Label for Site-Specific Modification of Antibodies
Boswell, C. A., Mařík, J., Elowson, M. J., Reyes, N. A., Ulufatu, S., Bumbaca, D., Yip, V., Mundo, E. E., Majidy, N., Hoy, M. V., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm401365h · Cited by 45
Novel Strategy for Preparing Dual-Modality Optical/PET Imaging Probes via Photo-Click Chemistry
Sun, L., Ding, J., Xing, W., Gai, Y., Sheng, J., & Zeng, D. (2016) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.6b00115 · Cited by 45
Zettlitz, K. A., Tsai, W. K., Knowles, S. M., Kobayashi, N., Donahue, T. R., Reiter, R. E., & Wu, A. M. (2018) · Journal of Nuclear Medicine · doi:10.2967/jnumed.117.207332 · Cited by 45
Kobayashi, K., Sasaki, T., Takenaka, F., Yakushiji, H., Fujii, Y., Kishi, Y., Kita, S., Shen, L., Kumon, H., & Matsuura, E. (2015) · Journal of Immunology Research · doi:10.1155/2015/268172 · Cited by 44
Munnink, T. H. O., Dijkers, E. C. F., Netters, S. J., Hooge, M. N. L., Brouwers, A. H., Haasjes, J. G., Schroder, C. P., & de Vries, E. G. E. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.4604 · Cited by 44
Dubash, S., Merchant, S., Heinzmann, K., Mauri, F. A., Lavdas, I., Inglese, M., Kozlowski, K., Rama, N., Masrour, N., Steel, J. F., et al. (2018) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-018-4098-9 · Cited by 44
Molecular imaging to enlighten cancer immunotherapies and underlying involved processes
van der Veen, E. L., Bensch, F., Glaudemans, A. W. J. M., Hooge, M. N. L., & de Vries, E. G. E. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.09.007 · Cited by 44
Krämer-Marek, G., Bernardo, M., Kiesewetter, D. O., Bağcı, U., Kuban, M., Aras, Ö., Zieliński, R., Seidel, J., Choyke, P. L., & Capala, J. (2012) · Journal of Nuclear Medicine · doi:10.2967/jnumed.111.100354 · Cited by 43
Schoffelen, R., der Weg, W. W.-V., Visser, E. P., Goldenberg, D. M., Sharkey, R. M., McBride, W. J., Chang, C., Rossi, E. A., van der Graaf, W. T. A., Oyen, W. J. G., et al. (2014) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-014-2742-6 · Cited by 43
Bailly, C., Gouard, S., Lacombe, M., Saëc, P. L., Chalopin, B., Bourgeois, M., Chouin, N., Tripier, R., Halime, Z., Haddad, F., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.23886 · Cited by 43
Mayer, K. E., Mall, S., Yusufi, N., Gosmann, D., Steiger, K., Russelli, L., Bianchi, H. D. O., Audehm, S., Wagner, R., Bräunlein, E., et al. (2018) · Theranostics · doi:10.7150/thno.27275 · Cited by 43
Dual-Modality ImmunoPET/Fluorescence Imaging of Prostate Cancer with an Anti-PSCA Cys-Minibody
Tsai, W. K., Zettlitz, K. A., Tavaré, R., Kobayashi, N., Reiter, R. E., & Wu, A. M. (2018) · Theranostics · doi:10.7150/thno.27679 · Cited by 43
Photochemical Conjugation and One‐Pot Radiolabelling of Antibodies for Immuno‐PET
Patra, M., Eichenberger, L. S., Fischer, G., & Holland, J. P. (2018) · Angewandte Chemie International Edition · doi:10.1002/anie.201813287 · Cited by 43
van Rij, C. M., Sharkey, R. M., Goldenberg, D. M., Frielink, C., Molkenboer‐Kuenen, J. D. M., Franssen, G. M., van Weerden, W. M., Oyen, W. J. G., & Boerman, O. C. (2011) · Journal of Nuclear Medicine · doi:10.2967/jnumed.110.086520 · Cited by 42
Bodet‐Milin, C., Ferrer, L., Rauscher, A., Masson, D., Rbah‐Vidal, L., Faivre-Chauvet, A., Cerato, E., Rousseau, C., Hureaux, J., Couturier, O., et al. (2015) · Frontiers in Medicine · doi:10.3389/fmed.2015.00084 · Cited by 42
van Brummelen, E. M. J., Huisman, M. C., der Veen, B. J. D. W., Nayak, T. K., Stokkel, M. P. M., Mulder, E. R., Hoekstra, O. S., Vugts, D. J., van Dongen, G. A. M. S., Verheul, H. M. W., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.25343 · Cited by 42
Natarajan, A., Patel, C. B., Ramakrishnan, S., Panesar, P. S., Long, S., & Gambhir, S. S. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1871 · Cited by 42
Tintelnot, J., Baum, N., Schultheiß, C., Braig, F., Trentmann, M., Finter, J., Fumey, W., Bannas, P., Fehse, B., Riecken, K., et al. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-0849 · Cited by 42
Helden, E. J. V., Elias, S. G., Gerritse, S. L., van Es, S. C., Boon, E., Huisman, M. C., van Grieken, N. C. T., Dekker, H., van Dongen, G. A. M. S., Vugts, D. J., et al. (2019) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-019-04555-6 · Cited by 42
Natarajan, A., Gowrishankar, G., Nielsen, C. H., Wang, S., Iagaru, A. H., Goris, M. L., & Gambhir, S. S. (2012) · Molecular Imaging and Biology · doi:10.1007/s11307-011-0537-8 · Cited by 41
Biodistribution and PET Imaging of Labeled Bispecific T Cell–Engaging Antibody Targeting EpCAM
Warnders, F. J., Waaijer, S. J. H., Pool, M., Hooge, M. N. L., Friedrich, M., van Scheltinga, A. G. T. T., Deegen, P., Stienen, S., Pieslor, P. C., Cheung, H. K., et al. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.168153 · Cited by 41
Targeting MT1-MMP as an ImmunoPET-Based Strategy for Imaging Gliomas
de Lucas, Á. G., Schuhmacher, A. J., Oteo, M., Romero, E., Cámara, J. A., Martino, A. D., Arroyo, A. G., Morcillo, M. Á., Squatrito, M., Martinez-Torrecuadrada, J. L., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0158634 · Cited by 41
Sijbrandi, N. J., Merkul, E., Muns, J. A., Waalboer, D. C. J., Adamzek, K., Bolijn, M., Montserrat, V., Somsen, G. W., Haselberg, R., Steverink, P. J. G. M., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-1900 · Cited by 41
Pickett, J. E., Thompson, J. M., Sadowska, A., Tkaczyk, C., Sellman, B. R., Minola, A., Corti, D., Lanzavecchia, A., Miller, L. S., & Thorek, D. L. J. (2018) · Bone Research · doi:10.1038/s41413-018-0014-y · Cited by 41
Cheal, S. M., Xu, H., Guo, H.-F., Patel, M., Punzalan, B. J., Fung, E. K., Lee, S., Bell, M. M., Singh, M., Jungbluth, A. A., et al. (2018) · Theranostics · doi:10.7150/thno.26585 · Cited by 41
Escorcia, F. E., Houghton, J. L., Abdel-Atti, D., Pereira, P. M. R., Cho, A., Gutsche, N. T., Baidoo, K. E., & Lewis, J. S. (2019) · Theranostics · doi:10.7150/thno.37098 · Cited by 41
Positron Emission Tomography Imaging of Tumor Angiogenesis with a 66Ga-Labeled Monoclonal Antibody
Engle, J. W., Hong, H., Zhang, Y., Valdovinos, H. F., Myklejord, D. V., Barnhart, T. E., Theuer, C. P., Nickles, R. J., & Cai, W. (2012) · Molecular Pharmaceutics · doi:10.1021/mp300019c · Cited by 40
Self-citationLütje, S., Rijpkema, M., Goldenberg, D. M., van Rij, C. M., Sharkey, R. M., McBride, W. J., Franssen, G. M., Frielink, C., Helfrich, W., Oyen, W. J. G., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0594 · Cited by 40
Houghton, J. L., Abdel-Atti, D., Scholz, W. W., & Lewis, J. S. (2017) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.6b01130 · Cited by 40
Radiomanganese PET Detects Changes in Functional β-Cell Mass in Mouse Models of Diabetes
Hernandez, R. T., Graves, S. A., Gregg, T., VanDeusen, H. R., Fenske, R. J., Wienkes, H. N., England, C. G., Valdovinos, H. F., Jeffery, J. J., Barnhart, T. E., et al. (2017) · Diabetes · doi:10.2337/db16-1285 · Cited by 40
Self-citationMolecular Imaging of IGF-1R in Cancer
Sun, Y., Sun, X., & Shen, B. (2017) · Molecular Imaging · doi:10.1177/1536012117736648 · Cited by 40
Manganese in PET imaging: Opportunities and challenges
Brandt, M., Cardinale, J., Rausch, I., & Mindt, T. L. (2019) · Journal of Labelled Compounds and Radiopharmaceuticals · doi:10.1002/jlcr.3754 · Cited by 40
O’Donoghue, J. A., Danila, D. C., Pandit-Taskar, N. D., Beylergil, V., Cheal, S. M., Fleming, S. E., Fox, J. J., Ruan, S., ZANZONICO, P. B., Ragupathi, G., et al. (2019) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.9b00326 · Cited by 40
Walther, M., Gebhardt, P., Grosse‐Gehling, P., Würbach, L., Irmler, I. M., Preusche, S., Khalid, M., Opfermann, T., Kamradt, T., Steinbach, J., et al. (2011) · Applied Radiation and Isotopes · doi:10.1016/j.apradiso.2011.02.040 · Cited by 39
Azad, B. B., Chatterjee, S., Lesniak, W. G., Lisok, A., Pullambhatla, M., Bhujwalla, Z. M., Pomper, M. G., & Nimmagadda, S. (2016) · Oncotarget · doi:10.18632/oncotarget.7111 · Cited by 39
Evaluation of Next-Generation Anti-CD20 Antibodies Labeled with89Zr in Human Lymphoma Xenografts
Yoon, J. T., Longtine, M. S., Marquez-Nostra, B. V., & Wahl, R. L. (2018) · Journal of Nuclear Medicine · doi:10.2967/jnumed.117.203299 · Cited by 39
Westerlund, K., Honarvar, H., Максимилианович, Т. В., & Karlström, A. E. (2015) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.5b00292 · Cited by 38
Cited by
Antibody–Drug Conjugates for Cancer Therapy
Hafeez, U., Parakh, S., Gan, H. K., & Scott, A. M. (2020) · Molecules · doi:10.3390/molecules25204764 · Cited by 395
Guo, X., Li, Y., Zhang, M., Cao, K., Tian, Y., Qi, Y., Li, S., Li, K., Yu, X., & Ma, L. (2020) · Angewandte Chemie International Edition · doi:10.1002/anie.202010829 · Cited by 345
Radiochemistry for positron emission tomography
Rong, J., Haider, A., Jeppesen, T. E., Josephson, L., & Liang, S. H. (2023) · Nature Communications · doi:10.1038/s41467-023-36377-4 · Cited by 294
Adverse Events Following Cancer Immunotherapy: Obstacles and Opportunities
Pauken, K. E., Dougan, M., Rose, N. R., Lichtman, A. H., & Sharpe, A. H. (2019) · Trends in Immunology · doi:10.1016/j.it.2019.04.002 · Cited by 280
Biomarkers for immunotherapy of hepatocellular carcinoma
Greten, T. F., Villanueva, A., Korangy, F., Ruf, B., Yarchoan, M., Ma, L., Ruppin, E., & Wang, X. W. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00816-4 · Cited by 227
“A variety of radionuclides and monoclonal antibodies have been used to develop immunoPET probes, which has been driven by advances in radiochemistry and conjugation strategies 152 .”
Background
Metadata
- Authors
- Wei, W., Rosenkrans, Z. T., Liu, J., Huang, G., Luo, Q.-Y., & Cai, W.
- Venue
- Chemical Reviews
- Publisher
- American Chemical Society (ACS)
- Published
- 2020-03-23
- Volume
- 120
- Issue
- 8
- Pages
- 3787-3851
- ISSN
- 0009-2665 (ISSN-L)
- 1520-6890
- OpenAlex
- W3012903956
- Cited by
- 484
- References
- 717
- FWCI
- 12.53
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.